Open AccessAn Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204)
Author(s) -
Jordan Berlin,
Yang Feng,
Paul J. Catalano,
James L. Abbruzzese,
Philip A. Philip,
Robert R. McWilliams,
Andrew M. Lowy,
Al B. Benson,
A. William Blackstock
Publication year - 2017
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000480295
Subject(s) - cetuximab , bevacizumab , medicine , gemcitabine , pancreatic cancer , oncology , chemotherapy , colorectal cancer , gastroenterology , cancer
Evaluate toxicity of two treatment arms, A (cetuximab) and B (bevacizumab), when combined with gemcitabine, and chemoradiation in patients with completely resected pancreatic carcinoma. Secondary objectives included overall survival (OS) and disease-free survival (DFS).